Procedural costs and cumulative pregnancy rate of natural cycle and different minimal stimulation IVF treatments compared to full stimulated IVF
This international multicenter study comparing natural cycle, minimal stimulation, and conventional full stimulated IVF protocols found that while natural cycle IVF has the lowest cost per cycle, minimal stimulation IVF using oral compounds combined with low-dose gonadotropins offers a cost-efficiency to achieve a 50% cumulative pregnancy rate comparable to conventional IVF.
Original paper licensed under CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). This is an AI-generated explanation of the paper below. It is not written or endorsed by the authors. For technical accuracy, refer to the original paper. Read full disclaimer
For decades, the path to building a family through in vitro fertilization has been paved with a specific assumption: to have the best chance of success, a woman must undergo a rigorous process of hormonal stimulation. This approach, known as conventional IVF, involves injecting daily doses of fertility drugs to coax the ovaries into producing a large batch of eggs at once. While this method has helped countless families, it is expensive, physically demanding, and carries risks of overstimulation. In recent years, a quieter movement has emerged, proposing that less might actually be more. These alternative strategies, ranging from natural cycle IVF (which uses no stimulation drugs at all) to minimal stimulation (which uses very low doses), aim to collect fewer eggs but with fewer side effects and lower costs. The central question for couples and doctors alike has remained unresolved: do these gentler, cheaper methods actually work as well as the heavy-duty standard, or do they simply save money by sacrificing the odds of a baby?
A team of researchers across several fertility centers in Germany and Switzerland set out to answer this by looking at the real-world experience of thousands of treatment cycles. They did not run a new experiment but rather analyzed data from 4,583 cycles performed between 2022 and 2023. Their goal was to compare five different treatment paths: the natural cycle, three variations of minimal stimulation, and the conventional full-stimulation method. They calculated the cost of every single step, from the price of the medication and blood tests to the laboratory fees and the salaries of the medical staff, using average European prices. Crucially, they did not just look at the cost of one attempt; they calculated how much it would cost to reach a specific milestone: a 50 percent chance of achieving a clinical pregnancy. This required them to estimate how many times a couple would need to try each method before hitting that success mark, accounting for cycles that fail due to premature ovulation or empty follicles.
The results painted a clear picture of trade-offs between cost, effort, and efficiency. The natural cycle, which involves no stimulation drugs, emerged as the cheapest option per single attempt, costing roughly 539 euros. However, because the success rate per attempt is lower, a couple would need to undergo five separate cycles to reach that 50 percent success threshold, bringing the total cost to about 2,695 euros. On the other end of the spectrum, the conventional full-stimulation IVF was the most expensive per attempt at 2,827 euros, but it was also the most efficient. Because it produces more eggs and embryos, a couple only needed two attempts—one fresh cycle and one frozen embryo transfer—to reach the same 50 percent success rate, totaling 3,413 euros.
The most significant finding lies in the middle ground. The researchers found that a specific type of minimal stimulation, which combines oral fertility medications with a very low dose of injectable hormones, offered a compelling balance. This hybrid approach cost about 1,134 euros per cycle. To reach the 50 percent success target, a couple would need three cycles, resulting in a total cost of 3,582 euros. This figure is remarkably close to the total cost of the conventional method, yet it requires fewer cycles than the natural approach and avoids the high drug costs and physical intensity of the full-stimulation protocol. The study suggests that for women in their mid-thirties with average ovarian function, this middle-ground strategy is a viable alternative that does not force a choice between financial burden and medical efficacy.
While the study highlights that the natural cycle is the least expensive per attempt, it also clarifies that it is the least efficient, requiring more time and more procedures to achieve the same result. Conversely, the conventional method remains the fastest route to a 50 percent success rate, needing the fewest number of cycles, but it comes with the highest upfront price tag and the highest physical toll. The researchers noted that their data comes from a large, real-world cohort, making the findings robust, though they acknowledged that costs can vary by country and that the study focused on procedural expenses rather than the broader economic impact of time off work or emotional stress. Ultimately, the work suggests that the landscape of fertility treatment is shifting; there is no longer a single "best" way to proceed. Instead, couples now have a clearer map showing that a gentler, hybrid approach can often match the financial and clinical outcomes of the traditional heavy-stimulation standard.
Drowning in papers in your field?
Get daily digests of the most novel papers matching your research keywords — with technical summaries, in your language.